{"id":30329,"date":"2024-11-18T17:37:00","date_gmt":"2024-11-18T12:07:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30329"},"modified":"2025-02-07T09:51:25","modified_gmt":"2025-02-07T04:21:25","slug":"cell-and-gene-therapy-for-parkinsons-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment","title":{"rendered":"The Future of Parkinson\u2019s Disease Treatment: Unlocking the Potential of Cell and Gene Therapy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f5d9993f745\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f5d9993f745\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment\/#Persistent_Gaps_in_Parkinsons_Disease_Treatment\" >Persistent Gaps in Parkinson\u2019s Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment\/#How_Cell_and_Gene_Therapies_Are_Changing_Parkinsons_Care\" >How Cell and Gene Therapies Are Changing Parkinson\u2019s Care?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment\/#Emerging_Cell_and_Gene_Therapies_Shaping_the_Future_of_Parkinsons_Disease_Treatment\" >Emerging Cell and Gene Therapies Shaping the Future of Parkinson\u2019s Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment\/#The_Road_Ahead_Challenges_and_Opportunities_in_Parkinsons_Disease_Cell_and_Gene_Therapies\" >The Road Ahead: Challenges and Opportunities in Parkinson\u2019s Disease Cell and Gene Therapies<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Parkinson\u2019s disease is the second most common neurodegenerative disorder after Alzheimer\u2019s disease. It affects about <strong>10 million<\/strong> people worldwide. The average age of onset for Parkinson\u2019s disease is <strong>around 60<\/strong>; however, approximately <strong>10-15%<\/strong> of patients experience early-onset PD before the <strong>age of 50<\/strong>.<\/p>\n\n\n\n<p>In 2023, there were <strong>2.7 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-epidemiology-forecast\">diagnosed prevalent cases of Parkinson\u2019s disease<\/a> in the 7MM. Of these, the United States accounted for <strong>45%<\/strong> of the cases, while Japan and Germany represented <strong>9%<\/strong> and <strong>18%<\/strong> of the cases, respectively, according to DelveInsight\u2019s estimates.<\/p>\n\n\n\n<p>As per the estimates, the gender distribution of the disease suggests a male predominance, with approximately <strong>54%<\/strong> male and <strong>46%<\/strong> female cases in the 7MM in 2023.&nbsp; Among the stage-specific diagnosed prevalent cases of Parkinson\u2019s disease in Japan, the highest cases were contributed by <strong>Stage III<\/strong> in 2023. Currently, there\u2019s no cure for Parkinson\u2019s, but treatments like medication, lifestyle changes, and deep brain stimulation can manage symptoms and improve quality of life.<\/p>\n\n\n\n<p><strong><em>To grab more knowledge on Parkinson\u2019s disease, visit our blog \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-therapeutic-market\"><strong><em>Evaluation of Rapidly Evolving Parkinson\u2019s Disease Therapeutic Market<\/em><\/strong><\/a><strong><em>\u201d<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-persistent-gaps-in-parkinson-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Persistent_Gaps_in_Parkinsons_Disease_Treatment\"><\/span><strong>Persistent Gaps in Parkinson\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Current Parkinson\u2019s disease treatments, including <strong>levodopa and dopamine agonists<\/strong>, mainly focus on managing symptoms rather than addressing the root cause of neuronal degeneration. As a result, their effectiveness declines over time, leading to issues such as motor fluctuations, dyskinesias, and non-motor symptoms, which significantly affect patients\u2019 quality of life. While several approved therapies target motor symptoms and enhance movement in Parkinson\u2019s disease patients, the US FDA recently approved <strong>CREXONT <\/strong>extended-release capsules in August 2024 for the treatment of Parkinson&#8217;s disease.<\/p>\n\n\n\n<p>CREXONT is a novel oral formulation of carbidopa\/levodopa (CD\/LD) that combines immediate-release (IR) granules and extended-release (ER) pellets. This medication is prescribed for the treatment of Parkinson\u2019s disease, Parkinson\u2019s disease caused by brain infections or inflammation, and Parkinson\u2019s-like symptoms resulting from carbon monoxide or manganese poisoning in adults. The ER pellets in CREXONT contain levodopa coated with a sustained-release polymer for gradual drug release, a mucoadhesive polymer to help the granules stay at the absorption site longer, and an enteric coating to prevent early breakdown in the stomach. This formulation is different from <strong>RYTARY<\/strong>, an extended-release CD\/LD treatment for Parkinson&#8217;s disease approved by the US FDA in 2015.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"479\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175613\/Parkinsons-Disease-Market-Key-Insights-1024x479.png\" alt=\"Parkinsons Disease Market Key Insights\" class=\"wp-image-30335\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175613\/Parkinsons-Disease-Market-Key-Insights-1024x479.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175613\/Parkinsons-Disease-Market-Key-Insights-300x140.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175613\/Parkinsons-Disease-Market-Key-Insights-150x70.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175613\/Parkinsons-Disease-Market-Key-Insights-768x359.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175613\/Parkinsons-Disease-Market-Key-Insights-1536x718.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175613\/Parkinsons-Disease-Market-Key-Insights.png 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Despite limited major <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">advancements in Parkinson\u2019s disease treatment<\/a> since levodopa\u2019s introduction, several unmet needs persist. The current Parkinson\u2019s disease market lacks curative or disease-modifying therapies, offering only symptomatic treatment through a multidisciplinary approach. Although medication and neurosurgical techniques have progressed over the decades, a significant gap remains in effectively managing motor symptoms. Improved control over tremors, gait and balance, posture, dexterity, and communication skills remain a major therapeutic challenge. Additionally, addressing psychosis in Parkinson\u2019s patients is another critical unmet need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-cell-and-gene-therapies-are-changing-parkinson-s-care\"><span class=\"ez-toc-section\" id=\"How_Cell_and_Gene_Therapies_Are_Changing_Parkinsons_Care\"><\/span><strong>How Cell and Gene Therapies Are Changing Parkinson\u2019s Care?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cell and gene therapies are revolutionizing the landscape of Parkinson\u2019s care, offering hope to patients who once faced limited options. Traditional treatments focus on managing symptoms, but these innovative therapies aim to tackle the root causes of the disease. By introducing healthy cells or correcting faulty genes, scientists are developing groundbreaking solutions that could slow, halt, or even reverse the progression of Parkinson\u2019s. This new era of precision medicine is pushing the boundaries of what was once thought possible, offering a glimpse of a future where Parkinson\u2019s no longer dictates patients\u2019 lives.<\/p>\n\n\n\n<p>With advancements in gene editing and cell-based treatments, Parkinson\u2019s therapies are becoming increasingly tailored to individual patients. Cell therapies, like stem cell-based treatments, aim to regenerate the brain cells lost to the disease, while gene therapies focus on repairing or replacing malfunctioning genes that contribute to neurodegeneration. This personalized approach holds the promise of more effective, long-lasting treatments that address the unique genetic and biological factors at play in each patient, paving the way for targeted solutions that could transform Parkinson\u2019s care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-emerging-cell-and-gene-therapies-shaping-the-future-of-parkinson-s-disease-treatment\"><span class=\"ez-toc-section\" id=\"Emerging_Cell_and_Gene_Therapies_Shaping_the_Future_of_Parkinsons_Disease_Treatment\"><\/span><strong>Emerging Cell and Gene Therapies Shaping the Future of Parkinson\u2019s Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cell and gene therapies are paving the way for groundbreaking <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">treatments for Parkinson\u2019s disease<\/a>, offering hope where traditional therapies have fallen short. By targeting the root causes of Parkinson\u2019s disease at the genetic and cellular levels, these innovative approaches aim to slow, stop, or even reverse the progression of this debilitating neurodegenerative disease. Advances in gene editing technologies like CRISPR, paired with regenerative cell therapies, are unlocking the potential to repair or replace damaged neurons, potentially restoring motor function and improving the quality of life for patients. The future of PD treatment is no longer just about symptom management, but about tackling the disease at its core.<\/p>\n\n\n\n<p>The potential of cell and gene therapies for Parkinson\u2019s is already being tested in clinical trials, with promising early results. As these therapies progress from the lab to the clinic, they\u2019re shifting the narrative around Parkinson\u2019s care from merely symptom management to actual disease modification. Patients participating in trials are already experiencing improvements in motor function and quality of life, sparking excitement among both clinicians and researchers.&nbsp;<\/p>\n\n\n\n<p>The cell and gene therapy in the Parkinson\u2019s disease market has a promising outlook. The current emerging <a href=\"https:\/\/www.delveinsight.com\/report-store\/cell-and-gene-therapy-in-parkinsons-disease-pipeline-insight\">cell and gene therapy in the Parkinson\u2019s disease pipeline<\/a> is robust; with various therapies being developed, some of which include <strong>MaavRx\u2019s gene therapy, MeiraGTx\u2019s AAV-GAD, Hope Biosciences\u2019 HB-adMSCs, Sumitomo Pharma\u2019s CT1-DAP001\/DSP-1083, Prevail Therapeutics\/Eli Lilly\u2019s PR001<\/strong> (LY3884961), and <strong>BlueRock Therapeutics\u2019 Bemdaneprocel (BRT-DA01)<\/strong>, among others.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"443\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-1024x443.png\" alt=\"Emerging Cell and Gene Therapies for Parkinson\u2019s Disease\" class=\"wp-image-30336\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-1024x443.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-300x130.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-150x65.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-768x332.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease-1536x664.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175649\/Emerging-Cell-and-Gene-Therapies-for-Parkinsons-Disease.png 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Apart from cell and gene therapies, a wide range of medications is currently being developed, including those targeting alpha-synuclein pathology, which is widely regarded as a key factor in the neurodegeneration associated with Parkinson&#8217;s disease. These treatments hold promise as potential disease-modifying therapies in the near to medium-term future. Coupled with various regenerative approaches, such as stem cell and gene therapies, advancements in Parkinson\u2019s disease treatments are expected in the coming years, with several new, effective options likely to emerge.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights\">emerging Parkinson\u2019s disease pipeline<\/a> is promising, with several late-stage drugs anticipated to enter the Parkinson\u2019s disease market in the coming years. These include <strong>Supernus Pharmaceuticals\/Britannia Pharmaceuticals\u2019 SPN-830 (apomorphine infusion pump), AbbVie\u2019s tavapadon, Pharma Two B\u2019s P2B001 (extended-release pramipexole and rasagiline), and Mitsubishi Tanabe Pharma Corporation (NeuroDerm)\u2019s ND0612 (levodopa\/carbidopa)<\/strong>, among others. The approval of these therapies could have a significant impact on market dynamics, though their success rates remain uncertain.<\/p>\n\n\n\n<p><strong><em>To know more about emerging Parkinson\u2019s disease therapies, read our blog \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/parkinsons-disease-treatment-market\"><strong><em>Most Promising Therapies in the Parkinson\u2019s Disease Treatment Market<\/em><\/strong><\/a><strong><em>\u201d<\/em><\/strong><\/p>\n\n\n\n<p>With continued advancements, we\u2019re on the cusp of a major breakthrough that could provide a lasting, transformative impact on Parkinson\u2019s treatment, offering renewed hope for those living with the condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-road-ahead-challenges-and-opportunities-in-parkinson-s-disease-cell-and-gene-therapies\"><span class=\"ez-toc-section\" id=\"The_Road_Ahead_Challenges_and_Opportunities_in_Parkinsons_Disease_Cell_and_Gene_Therapies\"><\/span><strong>The Road Ahead: Challenges and Opportunities in Parkinson\u2019s Disease Cell and Gene Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Parkinson\u2019s disease remains one of the most debilitating neurological disorders, with current treatments only addressing symptoms rather than halting or reversing disease progression. The future of Parkinson\u2019s disease therapy lies in groundbreaking cell and gene therapies, which have shown tremendous potential in preclinical and early clinical trials. However, the road ahead is not without significant challenges. Overcoming the complexities of delivering therapeutic genes or cells to targeted regions of the brain, navigating the regulatory landscape, and ensuring long-term safety and efficacy are hurdles that researchers and clinicians must clear to make these therapies a reality for patients.<\/p>\n\n\n\n<p>On the flip side, the opportunities for cell and gene therapies in Parkinson\u2019s disease are immense. Advancements in gene editing technologies like <a href=\"https:\/\/www.delveinsight.com\/report-store\/crisper-market-forecast\">CRISPR<\/a>, and the increasing understanding of the molecular mechanisms driving Parkinson\u2019s, are paving the way for more personalized and targeted treatments. By potentially correcting the genetic mutations causing Parkinson\u2019s disease or delivering neuroprotective genes, these therapies could significantly improve patients&#8217; quality of life and even delay disease onset. Moreover, with collaborations between biotech companies, research institutions, and advocacy groups, there is a concerted effort to address both the scientific and logistical challenges to move these therapies into the clinic.<\/p>\n\n\n\n<p>As the field progresses, new innovations and discoveries may dramatically reshape our approach to treating Parkinson\u2019s disease. With the right investment, collaboration, and clinical trials, cell and gene therapies have the potential to offer hope where conventional treatments fall short. The journey toward effective and accessible therapies for Parkinson&#8217;s patients is challenging but brimming with transformative possibilities, making it one of the most exciting areas in neurodegenerative disease research today.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/cell-and-gene-therapy-in-parkinson-disease\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-1024x194.png\" alt=\"Cell and Gene Therapy in Parkinson\u2019s Disease Market Outlook\" class=\"wp-image-30334\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175528\/Cell-and-Gene-Therapy-in-Parkinsons-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Parkinson\u2019s disease is the second most common neurodegenerative disorder after Alzheimer\u2019s disease. It affects about 10 million people worldwide. The average age of onset for Parkinson\u2019s disease is around 60; however, approximately 10-15% of patients experience early-onset PD before the age of 50. In 2023, there were 2.7 million diagnosed prevalent cases of Parkinson\u2019s disease [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30331,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[258,1826,22360,16835,6833,3422,6832,6831],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-30329","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-gene-therapy","tag-parkinsons-disease","tag-parkinsons-disease-cell-and-gene-therapy","tag-parkinsons-disease-cure","tag-parkinsons-disease-market","tag-parkinsons-disease-therapeutic-market","tag-parkinsons-disease-therapy","tag-parkinsons-disease-therapy-market","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cell and Gene Therapy in Parkinson\u2019s Disease Treatment | Insights<\/title>\n<meta name=\"description\" content=\"Cell and gene therapies are paving way for treatments for Parkinson\u2019s disease, offering hope where traditional therapies have fallen short.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cell and Gene Therapy in Parkinson\u2019s Disease Treatment | Insights\" \/>\n<meta property=\"og:description\" content=\"Cell and gene therapies are paving way for treatments for Parkinson\u2019s disease, offering hope where traditional therapies have fallen short.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-18T12:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-07T04:21:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175348\/cell-and-gene-therapy-for-parkinsons-disease-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cell and Gene Therapy in Parkinson\u2019s Disease Treatment | Insights","description":"Cell and gene therapies are paving way for treatments for Parkinson\u2019s disease, offering hope where traditional therapies have fallen short.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment","og_locale":"en_US","og_type":"article","og_title":"Cell and Gene Therapy in Parkinson\u2019s Disease Treatment | Insights","og_description":"Cell and gene therapies are paving way for treatments for Parkinson\u2019s disease, offering hope where traditional therapies have fallen short.","og_url":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-11-18T12:07:00+00:00","article_modified_time":"2025-02-07T04:21:25+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175348\/cell-and-gene-therapy-for-parkinsons-disease-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment","url":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment","name":"Cell and Gene Therapy in Parkinson\u2019s Disease Treatment | Insights","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175348\/cell-and-gene-therapy-for-parkinsons-disease-treatment.png","datePublished":"2024-11-18T12:07:00+00:00","dateModified":"2025-02-07T04:21:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Cell and gene therapies are paving way for treatments for Parkinson\u2019s disease, offering hope where traditional therapies have fallen short.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/cell-and-gene-therapy-for-parkinsons-disease-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175348\/cell-and-gene-therapy-for-parkinsons-disease-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175348\/cell-and-gene-therapy-for-parkinsons-disease-treatment.png","width":466,"height":284,"caption":"cell-and-gene-therapy-for-parkinsons-disease-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/11\/15175348\/cell-and-gene-therapy-for-parkinsons-disease-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s Disease Cell and Gene Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s Disease Cure<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapy market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s Disease Cell and Gene Therapy<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s Disease Cure<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease market<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapy<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapy market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 18, 2024","modified":"Updated on Feb 7, 2025"},"absolute_dates_time":{"created":"Posted on Nov 18, 2024 5:37 pm","modified":"Updated on Feb 7, 2025 9:51 am"},"featured_img_caption":"cell-and-gene-therapy-for-parkinsons-disease-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30329"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30329\/revisions"}],"predecessor-version":[{"id":30337,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30329\/revisions\/30337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30331"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30329"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30329"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}